Categories
Noticias

ICBAS aims to reduce the impact of medicines on human nutrition.

A project funded by the PRR developed a network to monitor the use of antimicrobials in dairy and pig farming operations.

The use of antimicrobials (AMU) in human and veterinary medicine contributes to maintaining health and well-being but simultaneously induces antimicrobial resistance (AMR). AMR is increasing and has become one of the main global threats to human and animal health and life, as well as to the environment in general. The adoption of global measures developed according to the “One Health” approach is necessary to contain the AMR pandemic.

In order to help mitigate the emergence of antimicrobial-resistant microorganisms in humans and animals, the Instituto de Ciências Biomédicas Abel Salazar (ICBAS) is leading a project that has already developed several interconnected web platforms. These platforms ensure a process for assessing disease situations in animals on dairy and pig farms, aiming to make the use of these medicines more sustainable and safer.

Read the full article here.

Source: Notícias UP; Image: Unsplash.

Categories
Noticias

Professor at ICBAS joins consortium to develop vaccine against mosquito-borne viruses.

It is a broad-spectrum vaccine targeting dengue, Zika, yellow fever, West Nile virus, and other flaviviruses, which cause over 100,000 deaths annually.

Experts in virology, immunology, biotechnology, and public health from ten institutions across seven European countries and the United States have come together to develop, over the next three years, an innovative vaccine, called Flavivaccine,against mosquito-borne flaviviruses with epidemic potential, such as dengue, Zika, yellow fever, and West Nile virus.

“Currently, there are no effective vaccines against several mosquito-borne flaviviruses with pandemic potential and, in cases where they do exist (such as the dengue vaccine), they often have limitations in terms of safety, efficacy, or accessibility,” explains Joana Tavares, researcher at i3S and Assistant Professor at ICBAS, who will lead the Portuguese team. She assures that Flavivaccine “has the potential to address these issues by providing a safe, effective, flexible, and rapidly deployable platform.”

Read the full article here.

Source: Notícias UP; Image: Unsplash.

This website uses cookies to provide a better browsing experience. By continuing to browse this website, you consent its use. You can change your cookie settings at any time in your browser settings Know more